Molecularly targeted drug therapy for hepatocellular carcinoma is a combination of the molecularly targeted drug doxorubicin (sorafenib) while the patient is undergoing interventional therapy. Doxorubicin is an oral antitumor drug that is the first drug approved for the treatment of systemic liver cancer and is the only drug proven to significantly prolong the overall survival time of patients with liver cancer. Its mechanism of action is to inhibit tumor cell proliferation and tumor neovascularization, which is the latest drug for the treatment of liver cancer at home and abroad. Doxorubicin (Sorafenib) is an oral multi-target, multi-kinase inhibitor, which can block tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), and inhibit tumor cell proliferation by blocking R al/M EK/ERK signaling pathway, thus exerting a dual inhibitory, multi-target blocking effect against HCC. . Several randomized, double-blind, parallel-controlled international multicenter phase II clinical studies have shown that sorafenib can delay the progression of HCC and significantly prolong the survival of patients with advanced HCC. Therefore, sorafenib can be used as a standard drug for patients with advanced HCC. In 2005, Doxorubicin became the first new drug for the treatment of advanced kidney cancer in more than a decade, and now it has been approved in more than 60 countries for the treatment of advanced kidney cancer. The European Commission approved Doxorubicin for the treatment of hepatocellular carcinoma. Molecular targeted therapy has unique advantages in controlling tumor proliferation, preventing and delaying recurrence and metastasis, and improving patients’ quality of life in HCC; high-level evidence of evidence-based medicine has fully demonstrated that sorafenib can prolong the survival of patients with advanced HCC, and the combination with other therapeutic drugs or methods may achieve better results.